Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 22;13(3):334-339.
doi: 10.1093/ckj/sfaa084. eCollection 2020 Jun.

SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience

Francesco Fontana  1 , Francesco Giaroni  2 , Monica Frisina  2 , Gaetano Alfano  1   2 , Giacomo Mori  1 , Leonardo Lucchi  1 , Riccardo Magistroni  1   2 , Gianni Cappelli  1   2
Affiliations

SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience

Francesco Fontana et al. Clin Kidney J. .

Erratum in

Abstract

Background: Dialysis patients are considered at high risk for COVID-19 and the infection can easily spread in dialysis units.

Methods: We conducted an observational single-centre cohort study to describe clinical characteristics, treatments and outcomes of dialysis patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We tested patients who presented symptoms or had contact with a confirmed case. We enrolled 15 patients positive for SARS-CoV-2.

Results: We tested 37 of 306 dialysis patients. Patients with SARS-CoV-2 infection were older (mean age 75.96 ± 11.09 years) and all had comorbidities. At presentation, most had interstitial infiltrates on chest X-ray, three-quarters had leucopenia and none had respiratory insufficiency. During follow-up, there was an increase in serum C-reactive protein and interleukin-6. Eighty percent of patients received supplemental oxygen; none received non-invasive ventilation, one was intubated. Most patients (80%) were treated with oral hydroxychloroquine for a median time of 6.5 days [interquartile range (IQR) 5-14.5] and 40% received azithromycin; two patients received a short course of antivirals and one received a single dose of tocilizumab. Only two patients did not require hospitalization. Of the nine survivors, eight still tested positive for SARS-CoV-2 a median of 19 days (IQR 9.25-23) after diagnosis. Six patients died (case fatality rate 40%) a median of 5.5 days (IQR 1.75-9.75) after diagnosis. The main reported cause of death was respiratory failure related to COVID-19 (five patients).

Conclusions: We report a single-centre experience of SARS-CoV-2 infection in dialysis patients. The disease showed a high case fatality rate and most patients required hospitalization. Survivors show prolonged viral shedding.

Keywords: COVID-19; SARS-CoV-2; dialysis.

PubMed Disclaimer

References

    1. Guan W, Ni Z, Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720 - PMC - PubMed
    1. Onder G, Rezza G, Brusaferro S.. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; doi:10.1001/jama.2020.4683 - PubMed
    1. Betjes M. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol 2013; 9: 255–265 - PubMed
    1. Basile C, Combe C, Pizzarelli F. et al. Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. Nephrol Dial Transplant 2020; doi:10.1093/ndt/gfaa069 - PMC - PubMed
    1. Kliger AS, Silberzweig J.. Mitigating risk of COVID-19 in dialysis facilities. Clin J Am Soc Nephrol 2020; doi:10.2215/CJN.03340320 - PMC - PubMed